Methods and compositions for the assessment of drug response
OwnerPatrick A. Gladding, Mark W. Websterinventors
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for predicting or determining a subject's response to an antiplatelet agent, and methods for determining a subject's suitability to a treatment regime or intervention for a disease associated with platelet aggregation, using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's response to an antiplatelet agent. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided
Claims25
A method comprising:
- a) analyzing a sample from a subject with a SNP detection assay to determine that said subject has a 636G>A (CYP2C19*3) polymorphism and/or a 19154G>A (CYP2C19*2) polymorphism, thereby generating a CYP2C19 genetic analysis result;
- and
- b) processing said CYP2C19 genetic analysis result with a computer system to generate an outcome that indicates that said subject should receive:
- i) a loading dose of clopidogrel on the first day of treatment being in a range of from above 600 mg to about 1800 mg, and
- ii) a maintenance dosage of said clopidogrel on subsequent days of treatment, said maintenance dosage being in the range of from above 50 mg to about 200 mg.
A method comprising:
- a) analyzing a sample from a subject with a SNP detection assay to determine that said subject has a 636G>A (CYP2C19*3) polymorphism and/or a 19154G>A (CYP2C19*2) polymorphism, thereby generating a CYP2C19 genetic analysis result;
- and
- b) processing said CYP2C19 genetic analysis result with a computer system to generate an outcome that indicates that said subject should receive:
- i) a first loading dosage of clopidogrel on the first day of treatment, said first loading dose being in a range of from above 300 mg to about 900 mg,
- ii) a second loading dosage of clopidogrel on said first day of treatment, said second loading dose being in a range of from above 300 mg to about 900 mg, and
- iii) a maintenance dosage of clopidogrel on subsequent days of treatment, said maintenance dosage being in the range of from above 50 mg to about 200 mg.
A method of treating a subject identified as a clopidogrel poor or non-responder, comprising:
- a) administering to the subject a loading dosage of clopidogrel on the first day of treatment, said loading dose being in a range of from above 600 mg to about 1800 mg;
- and
- b) administering to said subject a maintenance dosage of clopidogrel on subsequent days of treatment, said maintenance dosage being in the range of from above 50 mg to about 200 mg.
A method of treating a subject identified as a clopidogrel poor or non-responder, comprising:
- a) administering to the subject a first loading dosage of clopidogrel on the first day of treatment, said first loading dose being in a range of from above 300 mg to about 900 mg;
- b) administering to the subject a second loading dosage of clopidogrel on said first day of treatment, said second loading dose being in a range of from above 300 mg to about 900 mg;
- and
- c) administering to said subject a maintenance dosage of clopidogrel on subsequent days of treatment, said maintenance dosage being in the range of from above 50 mg to about 200 mg.
A kit for providing a plurality of dosage forms of clopidogrel comprising:
- a) a loading dose of said clopidogrel in a range of from above 600 mg to about 1800 mg, and
- b) a maintenance dose of said clopidogrel in a range of from above 50 mg to about 200 mg.
Dependencies are inferred from the claim text.